MetaCap

INmune Bio Inc. (INMB)

NASDAQ: INMBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.827-0.0671 (-7.50%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

INMB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$25.60M
EPS (TTM)
-$0.60
52-week range
0.8189 – 2.60
Day range
0.8189 – 0.9166
Volume / Avg
326.63K / 338.47K
Beta
—

52-week range

$0.8189$2.60

INMB stock today

INmune Bio (INMB) closed at $0.827 on Nov 20, down 7.50% (-$0.0671), versus the S&P 500's 3.70% decline. At this level, INMB sits near the bottom of its 52-week range of $0.8189 to $2.60: 68.2% below the high, set on Sep 8, 2026 and 1.0% above the low. INMB is down 47.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.2%.

INmune Bio has posted a net loss over the last twelve months (EPS of -$0.60), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About INmune Bio

Company profile

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. David J. Moss M.B.A.
Headquarters
Boca Raton, FL
Employees
21
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, INmune Bio generated $50,000 in revenue, up 257.1% from fiscal 2024. INmune Bio reported a net loss of $45.9 million, compared with a loss of $42.1 million a year earlier. Operating margin was -94766.0%.

INmune Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$50.00K$14.00K$155.00K$374.00K$181.00K
Growth+257.14%-90.97%-58.56%+106.63%+1545.45%
Net income$-45.93M$-42.08M$-30.01M$-27.30M$-30.34M
EPS (diluted)$-1.86$-2.11$-1.67$-1.52$-1.88

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$7.00+746.43%

  • Strong buy 1
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.24 vs —

INMB news

All INMB news

INmune Bio peers

Health Care sector
INMB peer companies
CompanyPrice% ChgMarket capCompare
PTHSPelthos Therapeutics Inc.6.38-8.73%$25.08Mvs INMB
LONALeonaBio Inc.2.02-17.89%$26.41Mvs INMB
SAENGenenta Science S.p.A. ADR0.5074-9.39%$24.47Mvs INMB
EXOZeXoZymes Inc.2.91-14.05%$27.42Mvs INMB
MGXMetagenomi Therapeutics Inc.0.565-7.95%$21.36Mvs INMB
CVMCel-Sci Corporation1.21-17.69%$21.28Mvs INMB
EVAXEvaxion A/S ADR2.25+10.84%$20.75Mvs INMB
KLRSKalaris Therapeutics Inc.1.28-5.19%$30.47Mvs INMB

Indexes, lists and sector

INmune Bio stock FAQ

What is INmune Bio's stock price today?

INMB last traded at $0.827 as of Nov 20, 4:00 PM EST, down 7.50% on the day. Prices are delayed at least 15 minutes.

Who is INmune Bio's CEO?

Mr. David J. Moss M.B.A. is the chief executive officer of INmune Bio Inc., which has about 21 employees.

What is the INMB 52-week high?

The 52-week high for INMB is $2.60 and the 52-week low is $0.8189. The stock is currently 68.2% below its high.

Compare INMB